Matthew Gregory Bursavich

This inventor holds 25 USPTO granted patents and 16 published patent applications and 8 EPO patents, primarily in Integrin Inhibitors. Top assignees: Morphic Therapeutic, Inc., Axovant Sciences Gmbh, Denali Therapeutics Inc.. Active years: 2005-2026.

USPTO Granted Patents = 25 (Patent Applications = 16)

% Patents Active = 80.0

EPO Patents = 8 (Patent Applications = 18)

Average Co-Inventor Count = 7.8

ph-index = 5

Forward Citations = 70(Granted Patents)

Location History:

Madison, WI (US) (2005)
Needham, MA (US) (2017 - 2023)

Company Filing History:

17 out of 17

Morphic Therapeutic, Inc.

patents

3 out of 8

Axovant Sciences Gmbh

patents

2 out of 57

Denali Therapeutics Inc.

patents

4. 2 out of 44

Ironwood Pharmaceuticals, Inc.

patents

5. 1 out of 4,237

Wisconsin Alumni Research Foundation

patents

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

Integrin Inhibitors

αvβ6 Integrin

α4β7 Antagonists

Nicotinic Receptors

Aminobenzisoxazole Compounds

Quinuclidine Amides

Imidazotriazinone Compounds

Fused Morpholinopyrimidines

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12552786 - Inhibitors of αvβ6 integrin (2026-02-17),

2. 12528803 - Inhibitors of αvβ6 integrin (2026-01-20),

3. 12459942 - Inhibiting (α-v)(β-6) integrin (2025-11-04),

4. 12415796 - Inhibitors of (αv)(β6) integrin (2025-09-16),

5. 12221416 - Antagonists of human integrin α4β7 (2025-02-11),

6. 12145935 - Inhibitors of (α-v)(β-6) integrin (2024-11-19),

7. 11827621 - Inhibitors of (α-v)(β-6) integrin (2023-11-28),

8. 11795167 - Inhibitors of (α-v)(β-6) integrin (2023-10-24),

9. 11739087 - Inhibiting (α-v)(β-6) integrin (2023-08-29),

10. 11370773 - Inhibiting human integrin (alpha-4) (beta-7) (2022-06-28),

11. 11174228 - Antagonists of human integrin (α4)(β7) (2021-11-16),

12. 11104661 - Inhibiting human integrin (α-4) (β-7) (2021-08-31),

13. 11046685 - Inhibitors of (α-v)(β-6) integrin (2021-06-29),

14. 11046669 - Inhibitors of (α-v)(β-6) integrin (2021-06-29),

15. 11040955 - Inhibitors of (alpha-v)(beta-6) integrin (2021-06-22),

Title: Matthew Gregory Bursavich: Innovator in Integrin Research

Introduction

Matthew Gregory Bursavich is a prominent inventor based in Needham, MA, known for his significant contributions to the field of integrin research. With a remarkable portfolio of 20 patents, Bursavich focuses on developing therapeutic strategies for various diseases through his innovative work on integrin antagonists and inhibitors.

Latest Patents

Bursavich's latest patents include groundbreaking work on small molecule antagonists of human integrin α4β7. These compounds offer potential treatments for a range of specific diseases or conditions. Additionally, he has developed small molecule inhibitors of the integrin αvβ6, expanding the scope of therapeutic options for various health issues.

Career Highlights

Throughout his career, Bursavich has worked with renowned organizations such as Morphic Therapeutics, Inc. and Axovant Sciences GmbH. His research contributions have been vital in pioneering new therapeutic approaches, positioning him as a leader in the biopharmaceutical industry. His dedication to addressing unmet medical needs through innovative solutions is evident in his extensive patent portfolio.

Collaborations

Bursavich has collaborated with talented professionals, including Bryce Alden Harrison and Aleksey I Gerasyuto. These partnerships reflect his commitment to advancing research and fostering innovative approaches within the scientific community.

Conclusion

Matthew Gregory Bursavich exemplifies the spirit of innovation in the field of integrin research. His 20 patents showcase his dedication to improving healthcare through targeted therapies, making a lasting impact on the industry and enhancing the lives of many patients. With continued efforts in research and collaboration, Bursavich is poised to contribute even further to medical advancements in the years to come.